|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Belinostat: clinical applications in solid tumors and lymphoma显示文摘 | Molife LR De Bono JS | 2011 | Expert Opin lnvestig Drugs2011，20，12： | 1 |
| 2 | A phaseⅠstudy of the safety and pharmacokinetics of the histonedeacetylase inhibitor belinostat administered in combina-tion with carboplatin and/or paclitaxel in patients with sol-id tumours显示文摘 | Lassen U Molife LR Sorensen M | 2010 | Br J Cancer2010，103，1： | 1 |
| 3 | predictive biomarkers for targeting insulin-like growth factor-1 (IGF-1)receptor显示文摘 | Carden CP Molife LR de Bono JS | | 0，，08： | 1 |
| 4 | A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709,an oral multi-targeted growth inhibitor (MTGI),in patients with advanced solid tumours显示文摘 | Scott EN Thomas AL Molife LR | 2009 | Cancer Chemother Pharmacol2009，64，2： | 1 |
| 5 | Phase 1 trial of the oral AKT inhibitor MN-2206 plus carboplatin/paclitaxel, do- cetaxel, or erlotinib in patients with advanced solid tumors显示文摘 | Molife LR Yan L Vitfelll Rasmussen J | 2014 | J H ematol Oncol2014，7，1： | 1 |
| 6 | Targeting cell cyclekinases and kineains in anlicancer drug development 显示文摘 | YapTA Molife LR Blagden SP | 2007 | Expert Opin Drug Discov2007，2，53： | 1 |
| 7 | Safety,pharmacokinet-ics,and preliminary activity of the anti-GF-1R antibody figitu-mumab (CP-51,871) in patients with sarcoma and Ewing's sarcoma:a phase 1 expansion cohort study显示文摘 | Olmos D Postel-Vinay S Molife LR | 2010 | Lancet Oncol2010，11，2： | 1 |
| 8 | Phase , two-stage, single- arm trial of the bistone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) 显示文摘 | Molife LR Attard G Fong PC | 2010 | Ann Oncol2010，21，1： | 1 |
| 9 | Safety,pharmacokinetics,and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma:A phase 1 expansion cohort study显示文摘 | Olmos D Postel-Vinay S Molife LR | 2010 | Lancet Oncol2010，11，2： | 1 |
| 10 | A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours 显示文摘 | Lassen U Molife LR Sorensen M | 2010 | Br J Cancer2010，103，1： | 1 |
| 11 | Targeting the DNA damage resp- onse in ontology: past, present and future perspectives显示文摘 | Basu B Yap TA Molife LR | 2012 | Curr Opin Oncol2012，24，3： | 1 |
| 12 | Targeting cell cycle kinases and kinesins in anticancer drug developmen显示文摘 | Yap TA Molife LR Blagden SP | | 0，，04： | 1 |
| 13 | Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing' s sarcoma: a phase 1 expansion cohort study显示文摘 | Olmos D Postel-Vinay S Molife LR | 2010 | Lancet Oncol2010，11，2： | 1 |
| 14 | A phase 1 dose escalation study of at9283, a small molecule inhibitor of aurora kinases, in pa- tients with advanced solid malignancies 显示文摘 | Arkenau HT Plummer R Molife LR | 2012 | Ann Oncol2012，23，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员